Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IN10018 in metastatic melanoma
NCT04109456Phase 1Completed
- Sponsor
- InxMed
- Start
- Mar 2020
- Primary completion
- Dec 2024
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 1, open-label trial of ifebemtinib in melanoma (3 arms), sponsored by InxMed. Primary endpoints: Safety and tolerability of IN10018 monotherapy at 21 days, Safety and tolerability of IN10018 in combination with cobimetinib at 28 days and 1 more. Started Mar 2020; status: completed.
02
Drugs
ifebemtinib
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT04109456.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04109456.